Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ATI-2138 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ATI-2138 | EXPERIMENTAL | ATI-2138 oral tablets BID |
| Name | Type | Description |
|---|---|---|
| ATI-2138 | DRUG | ATI-2138 Oral Tablets BID |
Inclusion Criteria: * Able to comprehend and willing to sign the IRB approved ICF/assent prior to administration of study-related procedures. * Male patients or non-pregnant, non-nursing female patients 18 to 60 years old, inclusive, at the time of informed consent/assent. * Have at least a 1-year ...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
ATI-2138 is an investigational small molecule being developed for the treatment of atopic dermatitis, a form of eczema. It is currently in Phase 2 clinical development and has been studied in adult participants with moderate to severe atopic dermatitis.
ATI-2138 is being developed by Aclaris Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ACRS. The company is conducting clinical research on this investigational drug for atopic dermatitis.
ATI-2138 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy for treating atopic dermatitis.
ATI-2138 has been studied in a Phase 2 clinical trial identified as NCT06585202, titled 'Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis.' This trial was conducted in the United States and enrolled 14 adult participants.
Yes, ATI-2138 is a small molecule drug. It is being developed as a therapeutic for atopic dermatitis, a dermatological condition. The drug is administered to adult participants with moderate to severe forms of the disease.